• Mashup Score: 0

    AstraZeneca announced that it will close the STRENGTH CV outcomes trial of omega-3 carboxylic acids in patients with mixed dyslipidemia at high risk for CVD.According to a press release from the company, the trial’s data monitoring committee recommended the trial be closed because of a low likelihood of omega-3 carboxylic acids (Epanova) demonstrating a benefit in the trial population.

    Tweet Tweets with this article
    • STRENGTH CV outcomes trial of omega-3 fatty acid stopped for futility #thingsthatdontwork https://t.co/i6d8OuUKOr

  • Mashup Score: 0

    Drug-eluting stent PCI of lipid-rich plaques by spectroscopic imaging did not adversely affect outcomes in the COLOR registry, researchers say. An editorialist said: ‘The results were not favorable.’

    Tweet Tweets with this article
    • Once again, we fail to predict the future. #thingsthatdontwork https://t.co/VklIghYjTa

  • Mashup Score: 0
    CPR, by Default - 4 year(s) ago

    When very old patients suffer cardiac arrest, doctors usually try to revive them — even if they were already near death.

    Tweet Tweets with this article
    • CPR, by Default https://t.co/OmeMuhhvN1 “patients over 80 with unwitnessed arrests and non-shockable rhythms, none survived to hospital discharge.” #Thingsthatdontwork

  • Mashup Score: 0

    Very low concentrations of high-sensitivity cardiac troponin did not allow the safe exclusion of inducible myocardial ischemia, according to a study published in the Annals of Internal Medicine. “While being integral to the diagnosis of acute myocardial infarction, circulating cardiac troponin I or T concentrations, even when measured with the most sensitive assays, cannot be used to

    Tweet Tweets with this article
    • High-sensitivity cardiac troponin may not exclude myocardial ischemia https://t.co/y5gceRSVka #thingsthatdontwork